Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
‘Incredibly rewarding’: FDA expands total artificial heart study after early success
An additional 15 patients will now receive BiVacor's titanium total artificial heart technology as they wait for a permanent transplant.
Cardiologists perform world’s first leadless LBBAP procedures with Abbott pacemaker
The first-in-human procedures were performed in Prague with the investigational Aveir CSP leadless pacemaker system.
Cardiologists work to standardize the diagnosis and management of acute myocarditis
New expert recommendations from the American College of Cardiology were designed to help cardiologists, primary care physicians, emergency physicians, rheumatologists and other clinicians deliver the best care possible when managing suspected myocarditis.
FDA approves J&J MedTech’s Impella heart pumps to treat pediatric patients
Johnson & Johnson MedTech partnered with the Advanced Cardiac Therapies Improving Outcomes Network to confirm these devices could safely and effectively treat younger patients.

FDA approves Farxiga for HF patients with reduced ejection fraction

The FDA has approved a new treatment option, Farxiga oral tablets, for adult heart failure patients with reduced ejection fraction.

May 6, 2020

TTVR improves outcomes for patients with severe tricuspid regurgitation

Transcatheter edge-to-edge tricuspid valve repair (TTVR) is an effective treatment option for patients with severe tricuspid regurgitation (TR), according to a new study published in JACC: Heart Failure.

April 13, 2020

Statins reduce risk of developing HF from breast cancer therapies

Key chemotherapy treatments are known to have a negative impact on cardiovascular health, even leading to heart failure (HF) in some patients.

March 23, 2020

HF patients with type 2 diabetes can safely be treated with liraglutide

Liraglutide, a common medication used to treat type 2 diabetes (T2D), is safe to use for heart failure (HF) patients, according to new findings published in the Journal of the American College of Cardiology.

March 18, 2020

Heart-failure patients lose years of life when air pollution is a neighbor

Long-term daily exposure to air pollution carrying fine particulate matter poses a significant risk of all-cause mortality for people with heart failure (HF).

March 16, 2020

LVAD recipients see heightened risk of suicide

Heart patients with implanted left ventricular assist devices are more likely to both attempt and succeed in committing suicide than other chronically ill patients, according to a study out of France.

March 13, 2020

Pop Goes the Pillbox: Will Polypharmacy Problems Limit the Adoption of SGLT2 Inhibitors?

Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?

March 13, 2020

Ablation continues to benefit patients with concomitant HF, AFib

A new analysis of the CASTLE-AF trial has found that catheter ablation for AFib remains effective in a much larger group of heart failure patients, cementing evidence first presented in early 2018.

March 4, 2020

Heart Failure

FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

‘Incredibly rewarding’: FDA expands total artificial heart study after early success

Cardiologists perform world’s first leadless LBBAP procedures with Abbott pacemaker

Cardiologists work to standardize the diagnosis and management of acute myocarditis

FDA approves J&J MedTech’s Impella heart pumps to treat pediatric patients